# Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

> **NCT00039429** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 180 (estimated)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** atrasentan hydrochloride

## Key facts

- **NCT ID:** NCT00039429
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07-14
- **Primary completion:** 2006-04
- **Final completion:** —
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039429, "Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00039429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*